Loading...
•
Mar 31, 2021
scPharmaceuticals Q1 2021 Earnings Report
Reported financial results for the first quarter ended March 31, 2021 and provided a business update.
Key Takeaways
scPharmaceuticals reported a net loss of $7.1 million for the first quarter of 2021, and ended the quarter with $96.5 million in cash, cash equivalents, restricted cash and investments. The company is focused on advancing FUROSCIX and expects to resubmit the NDA in the fall of 2021.
Conducted a Type A meeting with the FDA regarding the FUROSCIX NDA and requirements related to its resubmission.
The company is still in discussion with the FDA regarding the bench top testing of the West SmartDose Gen II on-body infusor.
Pending resolution of the testing plan, the company anticipates resubmitting the FUROSCIX NDA under the current 505(b)(2) approval pathway in the fall of 2021.
Ended the first quarter with cash, cash equivalents, restricted cash and investments of $96.5 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...